Literature DB >> 12138899

Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome.

Kazuya Tsuboi1, Makoto Yazaki, Hiroshi Miwa, Shinsuke Iida, Shogo Banno, Atsushi Wakita, Masakazu Nitta, Ryuzo Ueda.   

Abstract

A patient with Down syndrome (DS) at the time of diagnosis of acute lymphoblastic leukemia (ALL) had a relapse with acute myeloid leukemia (AML) after 4 years of complete remission. Although the diagnosis was AML, the leukemic blasts at relapse showed an immunoglobulin H rearrangement that turned out to be identical to that of the initial ALL blasts. It is thought that the leukemic precursor cells of this patient had the potential to differentiate into both lymphoid and myeloid lineages. This case is important for investigating target cells for leukemogenesis in DS.

Entities:  

Mesh:

Year:  2002        PMID: 12138899     DOI: 10.1007/bf02982721

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.

Authors:  U Creutzig; J Ritter; J Vormoor; W D Ludwig; C Niemeyer; I Reinisch; B Stollmann-Gibbels; M Zimmermann; J Harbott
Journal:  Leukemia       Date:  1996-11       Impact factor: 11.528

2.  The VDJ repertoire expressed in human preB cells reflects the selection of bona fide heavy chains.

Authors:  M Milili; C Schiff; M Fougereau; C Tonnelle
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

3.  Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.

Authors:  S Kojima; T Matsuyama; T Sato; K Horibe; S Konishi; M Tsuchida; Y Hayashi; H Kigasawa; Y Akiyama; J Okamura
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

4.  Acute myeloblastic leukemia (AML-M2) expressing CD19 B-cell lymphoid antigen without myeloid surface antigens.

Authors:  S H Khalil; J M Jackson; M H Qari; H Pyle
Journal:  Leuk Res       Date:  1994-02       Impact factor: 3.156

5.  Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group.

Authors:  L L Robison; M E Nesbit; H N Sather; C Level; N Shahidi; A Kennedy; D Hammond
Journal:  J Pediatr       Date:  1984-08       Impact factor: 4.406

6.  Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.

Authors:  Y Ravindranath; E Abella; J P Krischer; J Wiley; S Inoue; M Harris; A Chauvenet; C S Alvarado; R Dubowy; A K Ritchey
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

7.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

8.  The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia.

Authors:  S Raynaud; H Cave; M Baens; C Bastard; V Cacheux; J Grosgeorge; C Guidal-Giroux; C Guo; E Vilmer; P Marynen; B Grandchamp
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

9.  Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.

Authors:  A Zipursky; P Thorner; E De Harven; H Christensen; J Doyle
Journal:  Leuk Res       Date:  1994-03       Impact factor: 3.156

10.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.

Authors:  S P Romana; M Mauchauffé; M Le Coniat; I Chumakov; D Le Paslier; R Berger; O A Bernard
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.